[go: up one dir, main page]

Martin et al., 2024 - Google Patents

Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency

Martin et al., 2024

View PDF
Document ID
14922505635777667536
Author
Martin E
Winter S
Garcin C
Tanita K
Hoshino A
Lenoir C
Fournier B
Migaud M
Boutboul D
Simonin M
Fernandes A
Bastard P
Le Voyer T
Roupie A
Ben Ahmed Y
Leruez-Ville M
Burgard M
Rao G
Ma C
Masson C
Soudais C
Picard C
Bustamante J
Tangye S
Cheikh N
Seppänen M
Puel A
Daly M
Casanova J
Neven B
Fischer A
Latour S
Publication year
Publication venue
Nature

External Links

Snippet

Epstein–Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases,. The primary infection is often asymptomatic or causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder. Selective vulnerability to EBV has been …
Continue reading at hal.science (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Martin et al. Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency
Sureshchandra et al. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine
Izawa et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70–CD27 pathway in immunity to Epstein-Barr virus infection
Boutboul et al. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency
Martin et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation
Abolhassani et al. Combined immunodeficiency and Epstein-Barr virus–induced B cell malignancy in humans with inherited CD70 deficiency
Yun et al. Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells
Ju et al. Modulation of STAT‐3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells
Herrmann et al. Analysis of co-inhibitory receptor expression in COVID-19 infection compared to acute Plasmodium falciparum malaria: LAG-3 and TIM-3 correlate with T cell activation and course of disease
Pitard et al. Long-term expansion of effector/memory Vδ2− γδ T cells is a specific blood signature of CMV infection
Strauss et al. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin
Schmitt et al. IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans
Ronchetti et al. Glucocorticoid‐induced tumour necrosis factor receptor‐related protein: a key marker of functional regulatory T cells
Kared et al. Adaptive NKG2C+ CD57+ natural killer cell and Tim-3 expression during viral infections
Longhi et al. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease
Ji et al. HIV-1 binding to CD4 on CD4+ CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression
Huygens et al. Functional exhaustion limits CD4+ and CD8+ T-cell responses to congenital cytomegalovirus infection
Ambegaonkar et al. The differentiation in vitro of human tonsil B cells with the phenotypic and functional characteristics of T-bet+ atypical memory B cells in malaria
Govender et al. T cell perturbations persist for at least 6 months following hospitalization for COVID-19
Spoerl et al. Upregulation of CCR4 in activated CD8+ T cells indicates enhanced lung homing in patients with severe acute SARS‐CoV‐2 infection
Pillay et al. Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients
Cooper et al. Rapid GMP-compliant expansion of SARS-CoV-2–specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19
Ihantola et al. Effector T cell resistance to suppression and STAT3 signaling during the development of human type 1 diabetes
WO2009036521A1 (en) A method for identifying antigen-specific regulatory t cells
Tang et al. Characterization of age-related immune features after autologous NK cell infusion: Protocol for an open-label and randomized controlled trial